We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Spero Therapeutics Inc (SPRO) USD0.001

Sell:$0.92 Buy:$0.93 Change: $0.01 (1.06%)
NASDAQ:0.46%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.92
Buy:$0.93
Change: $0.01 (1.06%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.92
Buy:$0.93
Change: $0.01 (1.06%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). It is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The Company also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

Contact details

Address:
675 Massachusetts Ave Ste 14
CAMBRIDGE
02139-3309
United States
Telephone:
+1 (857) 2421600
Website:
https://sperotherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SPRO
ISIN:
US84833T1034
Market cap:
$30.85 million
Shares in issue:
32.82 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ankit Mahadevia
    President, Chief Executive Officer, Director
  • Satyavrat Shukla
    Chief Financial Officer
  • Cristina Larkin
    Chief Operating Officer
  • Tamara Joseph
    Chief Legal Officer
  • Timothy Keutzer
    Chief Development Officer
  • David Melnick
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.